Insulet (NASDAQ:PODD) Price Target Lowered to $210.00 at Piper Sandler

Insulet (NASDAQ:PODD) had its price target cut by Piper Sandler from $360.00 to $210.00 in a report issued on Wednesday,MarketScreener reports.

PODD has been the topic of several other research reports. TD Cowen downgraded shares of Insulet from a “buy” rating to a “hold” rating and set a $294.00 target price on the stock. in a research note on Monday, January 26th. Barclays reiterated an “underweight” rating and issued a $198.00 target price on shares of Insulet in a research note on Thursday. BTIG Research dropped their target price on shares of Insulet from $320.00 to $260.00 and set a “buy” rating on the stock in a research note on Wednesday. Canaccord Genuity Group dropped their target price on shares of Insulet from $435.00 to $249.00 in a research note on Thursday. Finally, Stifel Nicolaus dropped their target price on shares of Insulet from $350.00 to $250.00 in a research note on Thursday. Eighteen equities research analysts have rated the stock with a Buy rating, five have given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $263.91.

Insulet Trading Up 5.6%

Shares of NASDAQ PODD traded up $8.48 during midday trading on Wednesday, hitting $159.76. 400,010 shares of the company traded hands, compared to its average volume of 1,071,903. Insulet has a 12-month low of $148.30 and a 12-month high of $354.88. The company has a debt-to-equity ratio of 0.61, a quick ratio of 2.15 and a current ratio of 2.81. The stock has a 50-day moving average price of $212.92 and a 200 day moving average price of $264.96. The firm has a market cap of $11.06 billion, a P/E ratio of 45.64, a P/E/G ratio of 0.99 and a beta of 1.20.

Insulet (NASDAQ:PODD) last announced its quarterly earnings results on Wednesday, May 6th. The medical instruments supplier reported $1.42 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.19 by $0.23. Insulet had a net margin of 9.12% and a return on equity of 24.90%. The company had revenue of $761.70 million for the quarter, compared to analysts’ expectations of $729.89 million. During the same quarter in the previous year, the company earned $1.02 earnings per share. Insulet’s quarterly revenue was up 33.9% on a year-over-year basis. Insulet has set its FY 2026 guidance at 6.210- EPS. As a group, analysts expect that Insulet will post 6.27 earnings per share for the current year.

Insider Buying and Selling

In other Insulet news, Director Michael R. Minogue bought 2,030 shares of Insulet stock in a transaction on Wednesday, February 25th. The stock was acquired at an average cost of $246.23 per share, with a total value of $499,846.90. Following the completion of the acquisition, the director owned 17,483 shares in the company, valued at approximately $4,304,839.09. This represents a 13.14% increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Corporate insiders own 0.36% of the company’s stock.

Institutional Trading of Insulet

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Larson Financial Group LLC increased its stake in shares of Insulet by 114.6% in the fourth quarter. Larson Financial Group LLC now owns 88 shares of the medical instruments supplier’s stock worth $25,000 after purchasing an additional 47 shares in the last quarter. University of Texas Texas AM Investment Management Co. purchased a new stake in shares of Insulet in the fourth quarter worth $26,000. Elyxium Wealth LLC purchased a new stake in shares of Insulet in the fourth quarter worth $28,000. DV Equities LLC purchased a new stake in shares of Insulet in the fourth quarter worth $28,000. Finally, MV Capital Management Inc. purchased a new stake in shares of Insulet in the fourth quarter worth $29,000.

More Insulet News

Here are the key news stories impacting Insulet this week:

• Positive Sentiment: Q1 results beat expectations — EPS $1.42 vs. ~$1.19 consensus and revenue $761.7M (+33.9% Y/Y), driven by strong Omnipod demand. This confirms solid top-line momentum. Insulet Reports First Quarter 2026 Results
• Positive Sentiment: Company raised its annual revenue growth outlook after the quarter, citing sustained demand for its tubeless insulin pumps — a supportive signal for medium-term sales trajectory. Insulet lifts annual revenue forecast after quarterly beat
• Neutral Sentiment: Earnings call commentary was broadly upbeat (Omnipod growth emphasized) and management provided slide materials/transcripts for investors to parse execution details. These materials clarify drivers but don’t change the headline beat. Q1 2026 Earnings Call Transcript
• Negative Sentiment: FY 2026 EPS guidance appears below some Street estimates (company set FY EPS around ~6.21 vs. ~6.33 consensus cited by analysts), which likely disappointed investors despite the revenue upgrade. Earnings and guidance details
• Negative Sentiment: BTIG cut its price target from $320 to $260 (still a Buy rating); the PT reduction signals some analyst re‑valuation and may have amplified selling pressure. BTIG price target cut

Insulet Company Profile

Insulet Corporation is a medical device company headquartered in Acton, Massachusetts, that develops, manufactures and sells insulin-delivery systems for people with diabetes. The company’s core business is the design and commercialization of its Omnipod family of tubeless, wearable insulin pumps and the consumable Pods that deliver insulin. Insulet’s products aim to simplify insulin delivery for people with type 1 diabetes and insulin-requiring type 2 diabetes by offering an alternative to traditional insulin pens and tethered pump systems.

The company’s product portfolio includes the Omnipod System line—disposable, waterproof Pods that adhere to the skin and deliver insulin—and the associated controllers and mobile applications used to program and monitor insulin delivery.